- Home
- CHRS vs OCGN Comparison
CHRS vs OCGN Comparison
Compare CHRS & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- OCGN
- Stock Information
- Founded
- CHRS 2010
- OCGN 2013
- Country
- CHRS United States
- OCGN United States
- Employees
- CHRS N/A
- OCGN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRS Health Care
- OCGN Health Care
- Exchange
- CHRS Nasdaq
- OCGN Nasdaq
- Market Cap
- CHRS 191.3M
- OCGN 229.2M
- IPO Year
- CHRS 2014
- OCGN N/A
- Fundamental
- Price
- CHRS $1.32
- OCGN $0.75
- Analyst Decision
- CHRS Strong Buy
- OCGN Strong Buy
- Analyst Count
- CHRS 4
- OCGN 3
- Target Price
- CHRS $5.38
- OCGN $5.67
- AVG Volume (30 Days)
- CHRS 2.0M
- OCGN 6.4M
- Earning Date
- CHRS 03-12-2025
- OCGN 11-08-2024
- Dividend Yield
- CHRS N/A
- OCGN N/A
- EPS Growth
- CHRS N/A
- OCGN N/A
- EPS
- CHRS N/A
- OCGN N/A
- Revenue
- CHRS $304,340,000.00
- OCGN $4,700,000.00
- Revenue This Year
- CHRS $2.47
- OCGN N/A
- Revenue Next Year
- CHRS N/A
- OCGN N/A
- P/E Ratio
- CHRS N/A
- OCGN N/A
- Revenue Growth
- CHRS 44.19
- OCGN N/A
- 52 Week Low
- CHRS $0.66
- OCGN $0.50
- 52 Week High
- CHRS $2.87
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- CHRS 41.91
- OCGN 41.68
- Support Level
- CHRS $1.38
- OCGN $0.70
- Resistance Level
- CHRS $1.60
- OCGN $1.00
- Average True Range (ATR)
- CHRS 0.12
- OCGN 0.07
- MACD
- CHRS -0.03
- OCGN -0.01
- Stochastic Oscillator
- CHRS 1.10
- OCGN 17.93
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").